Newsfeed : FDA Warns That Truvada Ads Overstate the HIV Drug’s Long-Term Success

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Newsfeed » April 2010

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


April 13, 2010

FDA Warns That Truvada Ads Overstate the HIV Drug’s Long-Term Success

The U.S. Food and Drug Administration (FDA) warned pharmaceutical company Gilead Sciences Inc. that the print advertising for its HIV medication Truvada claims the drug is more effective in the long term than it really is, the San Francisco Business Times reports.

The ad in question shows photographs of a woman at a graduation, in an office setting and as a married woman sitting on a sofa. The text below the images reads, “With once a day Truvada for my HIV, I can plan for long-term success.”

“The print ad is false or misleading because it overstates the efficacy of Truvada, makes unsubstantiated claims and minimizes the risks associated with the drug,” the FDA regulatory review officer Aline Moukhtara said in a letter to Gilead’s director of regulator affairs, Joyce Acbay.

The FDA adds that the “totality of these claims and presentations misleadingly suggests” that HIV-positive people using Truvada can manage their viral load and increased CD4 count over the long term. However, the FDA claims that this efficacy “has not been demonstrated by substantial evidence or substantial clinical experience.”

The agency does note that Gilead points out in the ad, in a smaller font, that the drug was evaluated “through three years of a clinical study” and “proven over the long term…in three years of a clinical study.”

“However, this contextual information does not mitigate the overwhelming impression created by the prominent images and claims in the print ad, which suggest that patients can expect long-term treatment success with Truvada as they achieve their hopes and dreams, such as graduation, a career and marriage,” the FDA said. “Any of these goals can easily take more than three years to accomplish.”

Search: FDA, Truvada, HIV, CD4, Gilead, treatment, study

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (3 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.